The phase 1 CHRYSALIS trial investigated amivantamab (bi-specific antibody against EGFR and MET) +/− lazertinib (third-generation EGFR TKI) in patients with EGFR-mutant NSCLC who progressed on osimertinib [113]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.